Followers
|
3
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
79
|
Created
|
09/14/05
|
Type
|
Free
|
Moderators |
http://www.vasogen.com/home/flash
http://finance.yahoo.com/q/h?s=VSGN
Vasogen, Inc. is a biotechnology company engaged in the research and development of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. Our lead product, the Celacade™ technology, is designed to trigger the immune response to apoptosis — an important physiological process that regulates inflammation. Celacade is in late-stage development for the treatment of chronic heart failure and has received European regulatory approval under the CE Mark for this indication. We are also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders and are preparing to advance VP025, the lead drug candidate from this new class, into phase II development.
Gallery View 4: (Full Sto, MACD, Aroon8)